Publication:
Past, present, and future of therapies for pituitary neuroendocrine tumors: need for omics and drug repositioning guidance

Simple item page
dc.contributor.authorERDOĞAN, ONUR
dc.contributor.authorARĞA, KAZIM YALÇIN
dc.contributor.authorBOZKURT, SÜHEYLA
dc.contributor.authorBAYRAKLI, FATİH
dc.contributor.authorYILMAZ, BETÜL
dc.contributor.authorTURANLI, BESTE
dc.contributor.authorsAydin B., Yildirim E., ERDOĞAN O., ARĞA K. Y., Yilmaz B., BOZKURT S., BAYRAKLI F., TURANLI B.
dc.date.accessioned2023-03-06T08:13:57Z
dc.date.available2023-03-06T08:13:57Z
dc.date.issued2022-03-01
dc.description.abstractInnovation roadmaps are important, because they encourage the actors in an innovation ecosystem to creatively imagine multiple possible science future(s), while anticipating the prospects and challenges on the innovation trajectory. In this overarching context, this expert review highlights the present unmet need for therapeutic innovations for pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas. Although there are many drugs used in practice to treat PitNETs, many of these drugs can have negative side effects and show highly variable outcomes in terms of overall recovery. Building innovation roadmaps for PitNETs\" treatments can allow incorporation of systems biology approaches to bring about insights at multiple levels of cell biology, from genes to proteins to metabolites. Using the systems biology techniques, it will then be possible to offer potential therapeutic strategies for the convergence of preventive approaches and patient-centered disease treatment. Here, we first provide a comprehensive overview of the molecular subtypes of PitNETs and therapeutics for these tumors from the past to the present. We then discuss examples of clinical trials and drug repositioning studies and how multi-omics studies can help in discovery and rational development of new therapeutics for PitNETs. Finally, this expert review offers new public health and personalized medicine approaches on cases that are refractory to conventional treatment or recur despite currently used surgical and/or drug therapy.
dc.identifier.citationAydin B., Yildirim E., ERDOĞAN O., ARĞA K. Y., Yilmaz B., BOZKURT S., BAYRAKLI F., TURANLI B., "Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance", OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, cilt.26, sa.3, ss.115-129, 2022
dc.identifier.doi10.1089/omi.2021.0221
dc.identifier.endpage129
dc.identifier.issn1536-2310
dc.identifier.issue3
dc.identifier.startpage115
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/35172108/
dc.identifier.urihttps://hdl.handle.net/11424/287124
dc.identifier.volume26
dc.language.isotur
dc.relation.ispartofOMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Genetik
dc.subjectYaşam Bilimleri
dc.subjectBiyoteknoloji
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectInternal Medicine Sciences
dc.subjectMedical Genetics
dc.subjectLife Sciences
dc.subjectBiotechnology
dc.subjectMolecular Biology and Genetics
dc.subjectNatural Sciences
dc.subjectBİYOTEKNOLOJİ VE UYGULAMALI MİKROBİYOLOJİ
dc.subjectMikrobiyoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectGENETİK VE KALITIM
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectBIOTECHNOLOGY & APPLIED MICROBIOLOGY
dc.subjectMICROBIOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectGENETICS & HEREDITY
dc.subjectMOLECULAR BIOLOGY & GENETICS
dc.subjectGenetics
dc.subjectMolecular Biology
dc.subjectApplied Microbiology and Biotechnology
dc.subjectMolecular Medicine
dc.subjectGenetics (clinical)
dc.subjectpituitary neuroendocrine tumors
dc.subjectpituitary adenoma
dc.subjectsystems medicine
dc.subjectdrug repositioning
dc.subjectomics
dc.subjectpersonalized medicine
dc.subjectGLUCOCORTICOID-RECEPTOR ANTAGONIST
dc.subjectLONG-TERM TREATMENT
dc.subjectLOW-DOSE ETOMIDATE
dc.subjectCUSHINGS-SYNDROME
dc.subjectGROWTH-HORMONE
dc.subjectMEDICAL-TREATMENT
dc.subjectEUROPEAN-SOCIETY
dc.subjectADENOMAS
dc.subjectDISEASE
dc.subjectMANAGEMENT
dc.titlePast, present, and future of therapies for pituitary neuroendocrine tumors: need for omics and drug repositioning guidance
dc.typearticle
dspace.entity.typePublication
local.avesis.id3c57952b-2261-4b36-82dd-7814fb709b76
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication5faa02df-08e3-41e1-8a64-da8fbb7d5939
relation.isAuthorOfPublication3582c2d4-7fbb-4db7-8e90-75613782b894
relation.isAuthorOfPublicationdd039cf9-dfb8-4af0-b879-0b88c3a852fa
relation.isAuthorOfPublicationf8075bc9-c8f2-4422-839e-ed73fb5796a9
relation.isAuthorOfPublication81633a07-e5fb-4760-b3ef-bf0878d87827
relation.isAuthorOfPublication3e8c4f64-93ae-4b42-953c-35c8b07586b3
relation.isAuthorOfPublication.latestForDiscovery5faa02df-08e3-41e1-8a64-da8fbb7d5939

Files

Collections

Research Outputs